复发性IgG4相关疾病的治疗策略:一项前瞻性队列12年经验
该前瞻性队列纳入259例首次复发且随访超过12个月的IgG4-RD患者,比较仅强化糖皮质激素、仅强化免疫抑制剂、两者均强化三组的复发性复发结局;结果显示同时强化GC和IM较仅强化IM显著减少复发,决策树提示RI降至≤2且IgG4降幅≥25%者更可能无复发。
要点
- 复发时同时强化GC和IM较仅强化IM显著降低复发性复发风险(HR 0.29)。
- 仅强化GC有减少复发趋势但未达统计学显著(HR 0.51,95%CI 0.26-1.03)。
- 内脏受累亚组中上述差异更明显;RI≤2且IgG4降幅≥25%提示无复发。
核心结论
- 治疗IgG4-RD复发时,以GC为基础的治疗较仅调整IM与更低的复发性复发风险相关,尤其在内脏受累者中。
研究设计与样本
- 前瞻性IgG4-RD队列分析,纳入首次复发且随访超过12个月的患者,比较仅强化GC、仅强化IM、同时强化GC和IM三组。
主要发现
- 共纳入259例IgG4-RD患者,男性占61.7%,中位年龄54.0岁。
- 同时强化GC和IM者较仅强化IM者复发性复发更少(校正P 0.0002,HR 0.29,95%CI 0.16-0.52)。
- 仅强化GC者有复发性复发更少的趋势(校正P 0.0823,HR 0.51,95%CI 0.26-1.03)。
- 上述差异在内脏受累亚组中更明显。
- 决策树显示治疗后RI降至≤2且IgG4降幅≥25%者更可能无复发性复发,测试集AUC为0.728。
关键数值与推荐
- 主要结局为复发性复发;同时强化GC和IM对比仅强化IM的HR 0.29(95%CI 0.16-0.52,校正P 0.0002)。
- 仅强化GC对比仅强化IM的HR 0.51(95%CI 0.26-1.03,校正P 0.0823)。
- 决策树阈值:RI降至≤2且IgG4降幅≥25%,测试集AUC 0.728。
临床怎么用
- IgG4-RD首次复发时,尤其伴内脏受累者,可考虑同时强化GC和IM而非仅调整IM。
- 治疗后RI降至≤2且IgG4降幅≥25%可作为提示无复发性复发的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Relapse is common in IgG4-related disease (IgG4-RD). While previous studies focus on treatments for active IgG4-RD, data on the management of relapsing IgG4-RD remains limited. We aimed to investigate the treatment strategies for relapsing IgG4-RD. METHODS: This study analysed data prospectively collected from an IgG4-RD cohort, including patients who experienced their first relapse and were followed for over 12 months. We compared the outcome among three groups: (i) intensifying glucocorticoids (GC) only; (ii) intensifying immunosuppressants (IM) only; (iii) intensifying both GC and IM. The primary outcome was recurrent relapses. A decision tree model was developed to predict recurrent relapses. RESULTS: A total of 259 patients with IgG4-RD was included, with a male predominance (61.7%) and a median age of 54.0 years. Patients who intensified both GC and immunosuppressants (IM) (adjusted P 0.0002, HR 0.29, 95% CI: 0.16-0.52) experienced fewer relapses compared with those who intensified IM alone, while those who only intensified GC had a tendency to experience fewer relapses (adjusted P 0.0823, HR 0.51, 95% CI: 0.26-1.03). These differences were more pronounced in the subgroup with internal organ involvement. The decision tree indicated that those with an RI decrease to ≤2 and an IgG4 decrease ≥25% after treatment were more likely to stay free from recurrent relapses, with an AUC of 0.728 in the testing set. CONCLUSION: When treating relapse in IgG4-RD, GC-based treatment was associated with a lower hazard of recurrent relapse compared with only adjusting IMs, especially for those with internal organ involvement.
引用
- Nie Y, Zhang J, Jiang J, et al. Treatment strategies for relapsing IgG4-RD: 12-year experience from a prospective cohort. Rheumatology (Oxford). 2026. PMID: 42578729. doi:10.1093/rheumatology/keag401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。